

Case Report

Treatment of severe burn with DermACELL®, an acellular dermal matrix

Shyi-Gen Chen, Yuan-Sheng Tzeng, Chih-Hsin Wang

Department of Plastic and Reconstructive Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Received August 9, 2012; accepted August 30, 2012; Epub September 15, 2012; Published September 30, 2012

Abstract: For treatment of skin burn injuries, there exist several methods of treatment related to tissue regeneration, including the use of autograft skin and cryopreserved skin. However, each method has drawbacks. An alternative method for tissue regeneration is allograft acellular dermal matrix, with potential as a biocompatible scaffold for new tissue growth. One recently produced material of this type is DermACELL®, which was used in this case presentation for treating a scar resulting from second- and third-degree burns in a 33-year-old female patient. The patient presented with significant hypertrophic scarring from the elbow to the hand and with limited wrist and elbow motion. The scarring was removed, and the patient was treated with a 1:3 mesh of DermACELL. The wound was resurfaced with a split thickness skin graft, and postoperative care included application of pressure garment and silicone sheet, as well as range of motion exercise and massage. At 30 days after DermACELL application, the wound appeared well-healed with little scar formation. At 180 days post-application, the wound continued to appear healed well without significant scar formation. Additionally, the wound was supple, and the patient experienced significant improvement in range of motion. In the case presented, DermACELL appears to have been a successful method of treatment for scarring due to severe burns by preventing further scar formation and improving range of motion.

Keywords: Acellular dermal matrix, deep burn treatment, DermACELL®, scar prevention, wound healing, skin, contracture

Introduction

Burn injuries to the skin can be painful, and, if not healed properly, lead to issues such as abnormal scarring, limited range of motion, chronic non-healed wounds, and entry points for infection. In treating burns, while autograft skin is a common grafting material, it may be of limited supply and has associated comorbidities. Also, cryopreserved skin is an acceptable short-term covering for burns, but can need frequent replacement. Ultimately, a new host matrix must still be generated for optimal clinical results. An alternative matrix scaffold for new tissue generation is allograft acellular human dermal matrix as reviewed by Wainwright and Bury [1]. In theory, decellularization of human dermis serves to remove potentially immunogenic material and cellular remnants. This provides a clean, biocompatible scaffold for host cellular and vascular in-growth and, ultimately, new tissue regeneration. In addition to the treatment of

burns, decellularized human skin has been used for a variety of medical procedures; primarily wound healing, soft tissue reconstruction, and sports medicine applications [2-21].

A new decellularized dermal allograft has recently been introduced, trade-named DermACELL®. The patented [22] process used to prepare DermACELL includes the use of anionic detergents and endonuclease, resulting in a material with over 97% nucleic acid removal and acellular histological appearance. It is also terminally sterilized to a Sterility Assurance Level of 10^{-6} . In addition, DermACELL is preserved and stored at room temperature allowing the allograft to be maintained and delivered fully hydrated at ambient temperature to the surgical suite. Rapid in vivo cellular infiltration and vascularization of DermACELL has previously been demonstrated [23]. Both properties are advantageous in the treatment of wounds [24].



Figure 1. Pre-operative. Note the hypertrophic scarring on upper arm, elbow, forearm, wrist, dorsal hand. Demonstration of elbow and wrist motion limitation with elbow extension lag 45° and wrist extension lag 30°.



Figure 2. Intra-operative. Application of DermACELL (1:3) mesh and split thickness skin graft.

The following case presentation involves treating a severe burn scar contracture with this human acellularized dermal matrix, DermACELL®.

Materials and methods

The patient, a 33 year old female, suffered deep second to third degree burn injuries. Initial treatment consisted of antibiotic ointment and wound dressings. This resulted in a less than satisfactory outcome (see **Figure 1**), with significant scarring and poor range of motion. She presented three years later for additional treatment. Upon examination, as shown in **Figure 1**, the patient exhibited: hypertrophic scar from upper arm, elbow, whole forearm, wrist to dorsal hand; limitation of elbow and wrist motion; elbow extension lag 45°; wrist extension lag 30°.

The patient underwent the following treatments: excision of hypertrophic scar; and release of elbow and wrist contracture. DermACELL (1:3 mesh) was applied and trimmed to fit the wound (see **Figure 2**). DermACELL (LifeNet Health, Virginia Beach, VA, USA) is an acellular human dermal matrix, prepared using a combination of non-denaturing anionic detergent (N-Lauroyl sarcosinate, NLS), recombinant endonuclease (Benzonase®), and antibiotics (Polymixin B, Vancomycin, and Lincomycin). Following processing, it is terminally sterilized on dry ice using a low dose of gamma irradiation to achieve a sterility assurance level of 10^{-6} . The wound was resurfaced with thin split-thickness skin graft (4/1000 inch) **Figure 3**. Postoperative application of a pressure garment and silicone sheet was performed to prevent scar formation. Post-

Treatment of burn wound with acellular dermal matrix



Figure 3. Seven days post-operative. Complete take of DermACELL and autograft skin.



Figure 4. 30 days post-operative. Note well-healed wound with little scar formation.



Figure 5. 180 days post-operative. Note well-healed, supple wound without significant scar formation as well as markedly improved range of motion.

operative rehabilitation, including range of motion exercises and massage were executed.

Results

The patient condition at Day 30 is shown in **Figure 4**. As seen, the wound has healed well without significant scar formation and with good appearance, consistent with rapid cellular infiltration and revascularization as previously demonstrated in vivo with DermACELL [23]. As seen in **Figure 5** at 180 days post-DermACELL application, the wound heals well without significant scar formation. The wound is supple, and the patient has experienced dramatically improved range of motion.

Conclusions

In the case presented, DermACELL, a fully sterile and acellular human dermal matrix, was successfully used in conjunction with a thin split-thickness skin graft. This not only provided wound resurfacing for a scarred burn, but also prevented further scar formation and improved range of motion.

Acknowledgements

The author thanks Mia Bolling, BS and Mark Moore, PhD, LifeNet Health, for technical assistance in manuscript preparation.

Address correspondence to: Dr. Shyi-Gen Chen, Plastic and Reconstructive Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; No. 325, Sec. 2, Chenggong Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.). Tel: 886-2-8792-7195; Fax: 886-2-8792-7194; E-mail: shyigen@gmail.com, shyigen@ms26.hinet.net

References

- [1] Wainwright DJ, Bury SB. Acellular Dermal Matrix in the Management of the Burn Patient. *Aesthet Surg J* 2011; 31: 13S-23S.
- [2] Wong I, Burns J, Snyder S. Arthroscopic Graft-Jacket Repair of Rotator Cuff Tears. *J Shoulder Elbow Surg* 2010; 19: 104-109.
- [3] Snyder S and Bone J. Technique for Arthroscopic Replacement of Severely Damaged Rotator Cuff Using "GraftJacket" Allograft. *Operative Techniques in Sports Medicine* 2007; 15: 86-94.
- [4] Barber FA, Herbert MA, Boothby MH. Ultimate tensile failure loads of a human dermal allograft rotator cuff augmentation. *Arthroscopy* 2008; 24: 20-24.
- [5] Burkhead WZ, Schiffern SC, Krishnan SG. Use of Graft Jacket as an augmentation for massive rotator cuff tears. *Semin Arthroplasty* 2007; 18: 11-18.
- [6] Bond JL, Dopirak RM, Higgins J, Burns J, Snyder SJ. Arthroscopic replacement of massive, irreparable rotator cuff tears using a Graft-Jacket allograft: technique and preliminary results. *Arthroscopy* 2008; 24: 403-409.
- [7] Dopirak R, Bond JL, Snyder SJ. Arthroscopic total rotator cuff replacement with an acellular human dermal allograft matrix. *Int J Shoulder Surg* 2007; 1: 7-15.
- [8] Wilkins R. Acellular Dermal Graft Augmentation in Quadriceps Tendon Rupture Repair. *Current Orthopaedic Practice* 2010; 21: 315-319.
- [9] Lee DK. Achilles Tendon Repair with Acellular Tissue Graft Augmentation in Neglected Ruptures. *J Foot Ankle Surg* 2007; 46: 451-455.
- [10] Lee DK. A Preliminary Study on the Effects of Acellular Tissue Graft Augmentation in Acute Achilles Tendon Ruptures. *J Foot Ankle Surg* 2008; 47: 8-12.
- [11] Barber FA, Herbert MA, Coons DA. Tendon Augmentation Grafts: Biomechanical Failure Loads and Failure Patterns. *Arthroscopy* 2006; 22: 534-538.
- [12] Sbitany H, Sandeen S, Amalfi A, Davenport M, Langstein H. Acellular Dermis-Assisted Prosthetic Breast Reconstruction versus Complete Submuscular Coverage: A Head-to-Head Comparison of Outcomes. *Plast Reconstr Surg* 2009; 124: 1735-1740.
- [13] Nahabedian M. AlloDerm Performance in the Setting of Prosthetic Breast Surgery, Infection, and Irradiation. *Plast Reconstr Surg* 2009; 124: 1743-1753.
- [14] Salzberg A. Nonexpansive Immediate Breast Reconstruction Using Human Acellular Tissue Matrix Graft (AlloDerm). *Ann Plast Surg* 2006; 57: 1-5.
- [15] Kapfer S, Keshen T. The Use of Human Acellular Dermis in the Operative Management of Giant Omphalocele. *J Pediatr Surg* 2006; 41: 216-220.
- [16] Albo D, Awad S, Berger D and Bellows C. Decellularized human cadaveric dermis provides a safe alternative for primary inguinal hernia repair in contaminated surgical fields. *Am J Surg* 2006; 192: e12-e17.
- [17] Candage R, Jones K, Luchette F, Sinacore J, Vandevender D and Reed R. Use of human acellular dermal matrix for hernia repair: Friend or foe? *Surgery* 2008; 144: 703-711.
- [18] Mitchell C and Clma R. A novel technique for the repair of urostomal hernias using human acellular dermal matrix. *Urology* 2011; 77: 746-750.
- [19] Winters C, Brigido S, Liden B, Simmons M, Hartman J, Wright M. A Multicenter Study Involving the Use of a Human Acellular Dermal Regenerative Tissue Matrix for the Treatment of Diabetic

- Lower Extremity Wounds. *Adv Skin Wound Care* 2008; 21: 375-381.
- [20] Randall K, Booth B, Miller A, Russell C, Laughlin R. Use of an Acellular Regenerative Tissue Matrix in Combination with Vacuum-assisted Closure Therapy for Treatment of a Diabetic Foot Wound. *J Foot Ankle Surg* 2008; 47: 430-433.
- [21] Brigido SA, Boc SF, Lopez RC. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: A pilot study. *Orthopedics* 2004; 27: s145-s149.
- [22] US Patents 7,338,757; 6,743,574; 6,734,018.
- [23] Capito AE, Tholpady SS, Agrawal H, Drake DB, Katz AJ. Evaluation of Host Tissue Integration, Revascularization, and Cellular Infiltration Within Various Dermal Substrates. *Ann Plast Surg* 2012; 68: 495-500.
- [24] International Consensus. Acellular matrices for the treatment of wounds. An expert working group review. London: Wounds International, 2010.